Trial of Neoadjuvant Endostar, Docetaxel and Epirubicin for Patients With Breast Cancer

NCT01479036 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

800

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: docetaxel and epirubicin
DRUG: docetaxel and epirubicin plus endostatin

Sponsor

Xijing Hospital